Samsung Biologics secures two major contract manufacturing deals worth 930.4 billion won, surpassing 5 trillion won in total deals for 2023, marking a significant growth milestone.

The Swiss pharmaceutical manufacturer maintains an active strategy for seeking new technologies and alliances to improve drug transport to the brain, a critical challenge in developing medications for neurological diseases.